

Edgar Filing: Intellipharmaceutics International Inc. - Form 6-K

Intellipharmaceutics International Inc.  
Form 6-K  
July 27, 2017

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934

For the month of July 2017.

Commission File Number: 000-53805

Intellipharmaceutics International Inc.  
(Translation of registrant's name into English)

30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F [ x ] Form 40-F [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

This Report of Foreign Private Issuer on Form 6-K and the attached exhibit 99.1 shall be incorporated by reference into the Company's effective Registration Statements on Form F-3, as amended and supplemented (Registration Statement Nos. 333-172796 and 333-218297), filed with the Securities and Exchange Commission, from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished by Intellipharmaceutics International Inc. under the Securities Act of 1933 or the Securities Exchange Act of 1934.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Intellipharmaceutics International Inc.  
(Registrant)  
/s/ Domenic Della Penna  
Domenic Della Penna  
Chief Financial Officer

Date: July 26, 2017



EXHIBIT LIST

Exhibit Description

99.1 News Release dated July 26, 2017 - Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista™ (oxycodone hydrochloride extended release), an Abuse-Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain

> Consent of PricewaterhouseCoopers LLP (filed herewith)

23.2

Consent of Baker & Hostetler LLP (see Exhibit 5.1)

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Houston, State of Texas, on the 20th day of September, 2004.

QUANTA SERVICES, INC.

By: /s/ John R. Colson  
 John R. Colson  
 Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed on September 20, 2004, by the following persons in the capacities indicated below:

<b>SIGNATURE</b>	<b>TITLE (CAPACITY)</b>
* _____ John R. Colson * _____ James R. Ball * _____ Vincent D. Foster * _____ Bernard Fried * _____ H. Jarrell Gibbs * _____ Louis C. Golm * _____ Ben A. Guill * _____ Thomas J. Sikorski * _____ Gary A. Tucci	<p>Chief Executive Officer, Director                      (Principal Executive Officer)</p> <p>Director</p> <p>Director</p> <p>Director</p> <p>Director</p> <p>Director</p> <p>Director</p> <p>Director</p> <p>Director</p>



**Table of Contents**

\*

Director

---

John R. Wilson

By: \*/s/ Dana A. Gordon  
Dana A. Gordon  
Attorney-in-Fact

---



**Table of Contents**

**INDEX TO EXHIBITS**

- 5.1 Opinion of Baker & Hostetler LLP as to the legality of the securities being registered (filed herewith)
- 23.1 Consent of PricewaterhouseCoopers LLP (filed herewith)
- 23.2 Consent of Baker & Hostetler LLP (see Exhibit 5.1)